Clinical Trials - March 30, 2023
EXACT Therapeutics presents encouraging data
The company has presented data from two patients with liver metastases of colorectal cancer origin treated with ACT in the clinical Phase I ACTIVATE trial. The presented radiological results from these two patients suggest an improved response to standard of care chemotherapy in the tumors that are exposed to ACT treatment. This aligns well with […]
Clinical Trials - March 20, 2023
Affibody presents topline 12-week data
Affibody has announced that data from treatment with izokibep in the open label part (Part A) of a Phase 2b/3 trial in patients with moderate-to-severe Hidradenitis Suppurativa (HS) will be presented. The data from the open label Part A, presented at the American Academy of Dermatology (AAD) Annual Meeting in New Orleans, USA, demonstrated that […]
Clinical Trials - March 17, 2023
First patient dosed in Targovax study
Targovax has announced that the first patient has been dosed with cancer vaccine TG01 in the combination study with PD-1 checkpoint inhibitor (CPI) balstilimab in mutant RAS pancreatic cancer in the USA. The study is led by gastrointestinal cancer expert Dr. Anup Kasi in a three-way clinical collaboration between Kansas University Cancer Center (KUCC), Agenus […]
Clinical Trials - March 14, 2023
First patient dosed in BerGenBio Phase 1b/2a trial
The company has announced that the first patient was dosed in a trial evaluating bemcentinib in combination with the current standard of care, immune checkpoint inhibitor pembrolizumab and doublet chemotherapy, for the treatment of 1st line (1L) Non-Small Cell Lung Cancer (NSCLC) patients harboring STK11 mutations (STK11m). “Approximately 20% of non-squamous NSCLC patients harbor STK11m […]
Clinical Trials - March 13, 2023
Calliditas announces positive topline results
Calliditas Therapeutics has announced results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon versus placebo in patients with primary IgA nephropathy. The trial met its primary endpoint with Nefecon demonstrating a highly statistically significant benefit over placebo in estimated glomerular filtration rate (eGFR) over the two-year […]
Clinical Trials - February 27, 2023
Ascelia Pharma achieves major milestone
The company has announced the completion of the patient enrollment in the company’s phase 3 clinical study SPARKLE with the lead candidate drug Orviglance. “We are very pleased to have reached our enrollment target of 80 patients in the SPARKLE study within our recently updated timelines. This is a major milestone in the history of […]
